Literature DB >> 10722550

Production of hepatocyte growth factor during acute myocardial infarction.

Y Zhu1, Y Hojo, U Ikeda, K Shimada.   

Abstract

OBJECTIVE: To investigate the clinical significance of circulating hepatocyte growth factor (HGF) and the role of peripheral blood mononuclear cells (monocytes), which are a possible source of HGF, in patients with acute myocardial infarction. DESIGN AND PATIENTS: 37 patients with acute myocardial infarction and 13 normal control subjects were recruited. Peripheral venous blood samples were drawn from the infarct patients 1, 7, 14, and 21 days after onset. Monocytes were isolated from peripheral blood at those times. HGF concentrations in serum and in a culture medium of monocytes after incubation for 24 hours (monocyte HGF levels) were measured by enzyme linked immunosorbent assay.
RESULTS: Serum HGF and monocyte HGF values within seven days after onset of myocardial infarction were significantly higher than those of control subjects and decreased by day 14. There were significant positive correlations between serum HGF and monocyte HGF levels on day 7; between maximum plasma creatine phosphokinase levels and serum HGF levels on day 1; between maximum plasma C reactive protein and serum HGF levels; and between maximum C reactive protein and monocyte HGF levels. Monocyte HGF levels were raised in the patients with progression of ventricular enlargement in the course of acute myocardial infarction.
CONCLUSIONS: Early serum HGF concentrations reflect the extent of myocardial damage in acute myocardial infarction patients. Inflammation after acute myocardial infarction is supposed to be involved in enhanced HGF production. Monocytes may play an important role in ventricular remodelling after acute myocardial infarction by releasing the cardiovascular protective mitogen HGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722550      PMCID: PMC1729356          DOI: 10.1136/heart.83.4.450

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  31 in total

1.  Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment.

Authors:  K O Pietilä; A P Harmoinen; J Jokiniitty; A I Pasternack
Journal:  Eur Heart J       Date:  1996-09       Impact factor: 29.983

Review 2.  Hepatocyte growth factor: a multifunctional cytokine.

Authors:  P Boros; C M Miller
Journal:  Lancet       Date:  1995-02-04       Impact factor: 79.321

3.  International diagnostic criteria for acute myocardial infarction and acute stroke.

Authors:  R F Gillum; S P Fortmann; R J Prineas; T E Kottke
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

4.  Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor.

Authors:  Y Nakamura; R Morishita; J Higaki; I Kida; M Aoki; A Moriguchi; K Yamada; S Hayashi; Y Yo; H Nakano; K Matsumoto; T Nakamura; T Ogihara
Journal:  J Hypertens       Date:  1996-09       Impact factor: 4.844

5.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction.

Authors:  W K Lagrand; H W Niessen; G J Wolbink; L H Jaspars; C A Visser; F W Verheugt; C J Meijer; C E Hack
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

6.  Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes.

Authors:  R Morishita; S Nakamura; Y Nakamura; M Aoki; A Moriguchi; I Kida; Y Yo; K Matsumoto; T Nakamura; J Higaki; T Ogihara
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

7.  A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.

Authors:  Y Nakamura; R Morishita; S Nakamura; M Aoki; A Moriguchi; K Matsumoto; T Nakamura; J Higaki; T Ogihara
Journal:  Hypertension       Date:  1996-09       Impact factor: 10.190

8.  Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction.

Authors:  A Matsumori; Y Furukawa; T Hashimoto; K Ono; T Shioi; M Okada; A Iwasaki; R Nishio; S Sasayama
Journal:  Biochem Biophys Res Commun       Date:  1996-04-16       Impact factor: 3.575

9.  Expression of local hepatocyte growth factor system in vascular tissues.

Authors:  Y Nakamura; R Morishita; J Higaki; I Kida; M Aoki; A Moriguchi; K Yamada; S Hayashi; Y Yo; K Matsumoto
Journal:  Biochem Biophys Res Commun       Date:  1995-10-13       Impact factor: 3.575

Review 10.  Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction.

Authors:  E M Rosen; S K Nigam; I D Goldberg
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  12 in total

1.  Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET.

Authors:  Sebastian Vogel; Madhumita Chatterjee; Katja Metzger; Oliver Borst; Tobias Geisler; Peter Seizer; Iris Müller; Andreas Mack; Susanne Schumann; Hans-Jörg Bühring; Florian Lang; Rüdiger V Sorg; Harald Langer; Meinrad Gawaz
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

2.  Monocyte activation state regulates monocyte-induced endothelial proliferation through Met signaling.

Authors:  Shai Y Schubert; Alejandro Benarroch; Juan Monter-Solans; Elazer R Edelman
Journal:  Blood       Date:  2010-02-26       Impact factor: 22.113

3.  Unique patterns of cardiogenic and fibrotic gene expression in rat cardiac fibroblasts.

Authors:  Kittipong Tachampa; Tuempong Wongtawan
Journal:  Vet World       Date:  2020-08-26

4.  Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Elizabeth J Bell; Paul A Decker; Michael Y Tsai; James S Pankow; Naomi Q Hanson; Christina L Wassel; Nicholas B Larson; Kevin P Cohoon; Matthew J Budoff; Joseph F Polak; James H Stein; Suzette J Bielinski
Journal:  Atherosclerosis       Date:  2018-03-23       Impact factor: 5.162

Review 5.  Intestinal hormones and growth factors: effects on the small intestine.

Authors:  Laurie Drozdowski; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

6.  Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach.

Authors:  Shengjun Fan; Qiang Geng; Zhenyu Pan; Xin Li; Lu Tie; Yan Pan; Xuejun Li
Journal:  BMC Syst Biol       Date:  2012-12-10

7.  In vitro hepatic trans-differentiation of human mesenchymal stem cells using sera from congestive/ischemic liver during cardiac failure.

Authors:  Dillip Kumar Bishi; Santosh Mathapati; Kotturathu Mammen Cherian; Soma Guhathakurta; Rama Shanker Verma
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

8.  Hepatocyte growth factor predicts failure of Fontan circulation.

Authors:  Takuro Kojima; Moe Taki; Koichi Toda; Shota Muraji; Shigeki Yoshiba; Toshiki Kobayshi; Naokata Sumitomo
Journal:  ESC Heart Fail       Date:  2020-09-10

9.  Favorable Cardiovascular Health Is Associated With Lower Hepatocyte Growth Factor Levels in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Olatokunbo Osibogun; Oluseye Ogunmoroti; Richard A Ferraro; Chiadi E Ndumele; Gregory L Burke; Nicholas B Larson; Suzette J Bielinski; Erin D Michos
Journal:  Front Cardiovasc Med       Date:  2022-01-03

10.  An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.

Authors:  Massimiliano Mazzone; Cristina Basilico; Silvia Cavassa; Selma Pennacchietti; Mauro Risio; Luigi Naldini; Paolo M Comoglio; Paolo Michieli
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.